Thailand Restricts Weight-Loss Injection Pens With Doctor Prescriptions
Thailand's FDA reclassified weight-loss injection pens as controlled medicines requiring doctor prescriptions starting September 15, cracking down on counterfeit products and unsupervised use. A new tracking system will monitor the drugs fr
The Food and Drug Administration has reclassified GLP-1 receptor agonist injections, commonly called weight-loss pens, as controlled medicines requiring doctor's prescriptions from September 15 onwards. The decision follows reports of improper use without medical supervision, counterfeit products, unregistered drugs, and online sales outside official channels. FDA Secretary Supatra Bunserm said drugs like Liraglutide and Semaglutide are approved to treat type 2 diabetes and obesity, but have been misused by people seeking weight loss without medical oversight.
Pharmacies must now dispense these medications only with a doctor's prescription and pharmacist approval to ensure safe and appropriate use. The FDA will tighten controls through a Track & Trace system that monitors the drug from import through patient delivery, helping prevent leakage of counterfeit and unregistered products into the market. Violators face criminal charges and fines; illegal advertising carries penalties up to 100,000 baht.
The FDA clarified that the measure does not restrict access for eligible patients under medical care. The public can verify licensed GLP-1 products by entering the serial number from the package into the Track & Trace menu on the FDA website at www.fda.moph.go.th. Anyone finding discrepancies or suspecting counterfeits should contact the FDA hotline at 1556 or use the Oryor Smart Application available 24/7 to report violations.
